secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001077183-24-000153
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q3 revenue up 10% to $168M; adjusted EBITDA up 305%, raises FY guidance to $37-40M
--------------------------------------------------------------------------------

- Consolidated revenue $168M (+10% YoY); Clinical Services revenue $146M (+14%) with test volume +9%.
- Net loss decreased 4% to $18M; adjusted EBITDA improved 305% to $13M, fifth consecutive positive quarter.
- FY 2024 adjusted EBITDA guidance raised to $37-40M (from $33-37M); revenue guidance unchanged at $655-667M.
- Board appointed Felicia Williams; initial equity award ~$140,000 vesting June 1, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/0001077183-24-000153-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718324000153/neo-20241101.htm
  HTML page:      https://secwatch.observer/filing/0001077183-24-000153

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer